Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy: Technical note

Kidney International

Volumn 54, Issue 6, 1998, Pages 2146-2150

  Gaspari, Flavio ^a,b   Perico, Norberto ^a   Signorini, Orietta ^a   Caruso, Raffaele ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

AUC; Graft survival; Immunosuppression; Pharmacokinetic profile; Stepwise regression analysis

Indexed keywords

CYCLOSPORIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 0031756469     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00194.x     Document Type: Article

References (21)

1. STARZL TE, KLINTMALM GBG, PORTER KA, IWATSUKI S, SCHROTER GPJ: Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 305:266-269, 1981
2. MACOVIAK JA, OYER PE, STINSON EB, JAMIESON SW, BALDWIN JC, SHUMWAY NE: Four-year experience with cyclosporine for heart and heart-lung transplantation. Transplant Proc 17(Suppl 2):97-101, 1985
3. THE CANADIAN MULTICENTRE TRANSPLANT STUDY GROUP: A randomized clinical trial of cyclosporine in cadaveric renal transplantation: Analysis at three years. N Engl J Med 314:1219-1225, 1986
4. TRAEGER J, DUBERNARD J, POZZA G: Influence of immunosuppressive therapy on the endocrine function of segmental pancreatic allografts. Transplant Proc 15:1326-1329, 1983
5. KAHAN BD: Cyclosporine. N Engl J Med 321:1725-1738, 1989
6. KLINTMALM GBG, SÄWK J, RINGDÉN O, VON BAHR C, MAGNUSSON A: Cyclosporine plasma levels in renal transplant patients: Association with renal toxicity and allograft rejection. Transplantation 39:132-137, 1985
7. LINDHOLM AS, KAHAN BD: Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 54:205-218, 1993
8. GREVEL J, WELSH MS, KAHAN BD: Cyclosporine monitoring in renal transplantation: Area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 11:246-248, 1989
9. GASPARI F, RUGGENENTI P, TORRE L, BERTOCCHI C, REMUZZI G, PERICO N: Failure to predict cyclosporine area under the curve using a limited sampling strategy. Kidney Int 44:436-439, 1993
10. MUELLER EA, KOVARIK JM, VAN BREE JB, GREVEL J, LUCKER PW, KUTZ K: Influence of a fat reach meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 11:151-155, 1994
11. TRULL AK, TAN KKC, TAN L, ALEXANDER GJ, JAMIESON NV: Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 39:627-631, 1995
12. WINKLER M, RINGE B, OLDHAFER K, FARBER L, MAIBUCHER A: Influence on bile on cyclosporine absorption from microemulsion formulation in primary liver transplant. Transplant Int 8:324-326, 1995
13. MUELLER EA, KOVARIK JM, VAN BREE JB, LISON A, KUTZ K: Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients-A concentration-controlled comparison with the commercial formulation. Transplantation 57: 1178-1182, 1994
14. GASPARI F, ANEDDA MF, SIGNORINI O, REMUZZI G, PERICO N: Prediction of cyclosporine area under the curve, using a three-point sampling strategy after Neoral™ administration. J Am Soc Nephrol 8:647-652, 1997
15. AMANTE AJ, KAHAN BD: Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Transplant Proc 28:2162-2163, 1996
16. KEOWN P, LANDSBERG D, HALLORAN P, SHOKER A, RUSH D, JEFFERY J, RUSSELL D, STILLER C, MUIRHEAD N, COLE E, PAUL L, ZALTZMAN J, LOERTSCHER R, DALOZE P, DANDAVINO R, BOUCHER A, HANDA P, LAWEN J, BELITSKY P, PARFREY P: A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Transplantation Study Group. Transplantation 62:1744-1752, 1996
17. FORADORI AC, MARTINEZ L, ELBERG A, VACCAREZZA A, LOVELUCK A, PINTO C: Preliminary pharmacokinetic evaluation of a new galenical formulation of oral cyclosporine A: Neoral. Transplant Proc 27:1813-1814, 1995
18. SERAFINOWICZ A, GACIONG Z, BACZKOWSKA T, RELL K, LAO M: Limited sampling strategy to estimate exposure to CsA in renal allograft recipients (RARs) treated with Sandimmun-Neoral (NEO). (abstract) Second International Conference on New Trends in Clinical and Experimental Immunosuppression, Geneva, February 15-18, 1996, p 59
19. AMANTE AJ, KAHAN BD: Abbreviated Area-Under-the-Curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period. Clin Chem 42:1294-1296, 1996
20. LINDHOLM A, NAPOLI K, RUTZKY L, KAHAN BD: Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for trough concentration and urea under the curve monitoring of cyclosporine in renal transplantation. Ther Drug Monit 14:292-300, 1992
21. BLAND JM, ALTMAN DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310, 1986